Theranostics for COVID-19 Antiviral Drugs: Prospects and Challenges for Worldwide Precision/Personalized Medicine
- 1 January 2023
- journal article
- review article
- Published by Mary Ann Liebert Inc in OMICS: A Journal of Integrative Biology
- Vol. 27 (1), 6-14
- https://doi.org/10.1089/omi.2022.0151
Abstract
Coronavirus disease 2019 (COVID-19) is a systemic disease that impacts multiple organ systems with a complex clinical presentation and outcomes that can vary from person to person and between populations. To optimize COVID-19 treatment outcomes, and in light of the availability of antiviral drugs, there is a need for greater attention to the field of theranostics, the fusion of therapeutics and diagnostics. Theranostics tests would be invaluable, we suggest in this expert review, so as to optimize the efficacy and safety of current and future antiviral drugs against COVID-19. Theranostics would also assist in the design and implementation of clinical trials with antiviral drug candidates. We discuss here theranostics considering drugs such as remdesivir, Paxlovid™, and molnupiravir. All in all, we underscore that theranostics as a concept and practice is essential for efficient and safe health interventions against COVID-19 and other ecological crises in the 21st century.Keywords
This publication has 62 references indexed in Scilit:
- Expression Patterns of Organic Anion Transporting Polypeptides 1B1 and 1B3 Protein in Human Pediatric LiverDrug Metabolism and Disposition, 2016
- Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeysNature, 2016
- Interethnic variation of CYP2C19 alleles, ‘predicted’ phenotypes and ‘measured’ metabolic phenotypes across world populationsThe Pharmacogenomics Journal, 2015
- Distribution of CYP2D6 Alleles and Phenotypes in the Brazilian PopulationPLOS ONE, 2014
- Interethnic variability ofCYP2D6alleles and of predicted and measured metabolic phenotypes across world populationsExpert Opinion on Drug Metabolism & Toxicology, 2014
- Theranostics: A treasured tailor for tomorrowJournal of Pharmacy and Bioallied Sciences, 2014
- Very important pharmacogene summaryPharmacogenetics and Genomics, 2011
- Pharmacogenomic adaptation of antiretroviral therapy: overcoming the failure of lopinavir in an African infant with CYP2D6 ultrarapid metabolismEuropean Journal of Clinical Pharmacology, 2009
- Shifting emphasis from pharmacogenomics to theragnosticsNature Biotechnology, 2006
- Down‐regulation of human CYP3A4 by the inflammatory signal interleukin 6: molecular mechanism and transcription factors involvedThe FASEB Journal, 2002